A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid

Investigational New Drugs

Volumn 14, Issue 3, 1996, Pages 325-335

  Laohavinij, Sudsawat ^a   Wedge, Stephen R ^a   Lind, Micheal J ^a   Bailey, Nigel ^a   Humphreys, Alison ^a   Proctor, Madeleine ^a   Chapman, Fiona ^a   Simmons, Dorothy ^a   Oakley, Avril ^a   Robson, Lesley ^a   Gumbrell, Lyndsey ^a   Taylor, Gordon A ^a   Thomas, Huw D ^a   Boddy, Alan V ^a   Newell, David R ^a   Calvert, A Hilary ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

DDATHF; Lometrexol; Lometrexol and folic acid; Lometrexol clinical efficacy; Lometrexol toxicity

Indexed keywords

FOLIC ACID ANTAGONIST; FOLINIC ACID; LOMETREXOL; METHOTREXATE; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PURINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; ENZYME INHIBITION; FEMALE; FOLIC ACID BLOOD LEVEL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MUCOSA INFLAMMATION; MYALGIA; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PURINE SYNTHESIS; THROMBOCYTOPENIA; TOXICITY;

ACYLTRANSFERASES; ADMINISTRATION, ORAL; ADULT; AGED; ANTIDOTES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, INVESTIGATIONAL; ENZYME INHIBITORS; FEMALE; FOLIC ACID; FOLIC ACID ANTAGONISTS; GASTROINTESTINAL DISEASES; HUMANS; HYDROXYMETHYL AND FORMYL TRANSFERASES; KIDNEY DISEASES; LEUCOVORIN; MALE; MIDDLE AGED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; TETRAHYDROFOLATES;

EID: 0029808129     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00194536     Document Type: Article

References (35)

1. Taylor EC, Harrington PJ, Fletcher SR, Beardley GP, Moran RG: Synthesis of the antileukemic agents 5,10-dideazaaminopterin and 5,10-dideaza-5,6,7,8-tetra-hydroaminopterin. J Med Chem 28:914-921, 1985
2. Beardsley GP, Moroson BA, Taylor EC, Moran RG: A new folate antimetabolite, 5,10-Dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis. J Biol Chem 264:328-333, 1989
3. Jansen G, Westerhof GR, Kathmann I, Rijksen G, Schornagel JH: Growth-inhibitory effects of 5,10-dideazatetrahydrofolic acid on variant murine L1210 and human CCRF-CEM leukemia cells with different membrane transport characteristics for (anti)folate compounds. Cancer Chemother Pharmacol 28:115-117, 1991
4. Shih C, Grindey GB, Houghton PJ, Houghton JA: In vivo antitumour activity of 5,10-Dideazatetrahydrofolic acid (DDATHF) and its diastereomeric isomers. Proc Amer Assoc Cancer Res 29:283, 1988
5. Nelson R, Butler F, Dugan W Jr, Davisland C, Stone M, Dyke R: Phase I clinical trial of LY264618 (dideazatetrahydrofolic acid; DDATHF). Proc Amer Soc Clin Oncol 9:76, 1990
6. Ray MS, Muggia FM, Leichman CG, Grunberg SM, Nelson RL, Dyke RW: Phase I study of (6R)-5,10-Dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis. J Natl Cancer Inst 85:1154-1159, 1993
7. Pagani O, Sessa C, Dejong J, Kem H, Hatty H, Schmit H, Cavalli F: Phase I study of lometrexol (DDATHF) given in combination with leucovorin. Proc Amer Soc Clin Oncol 11:109, 1992
8. Lometrexol LY 264618 Clinical Investigation Brochure: Subchronic studies, mice 3.30; 3.2, 1992
9. Young C, Currie V, Baltzer L, Trochanowski B, Eton O, Dyke R, Bowsher R: Phase I and clinical pharmacologic study of LY264618, 5,10-dideazatetrahydrofolate. Proc Amer Assoc Cancer Res 31:177, 1990
10. Grindey GB, Alati T, Shih C: Reversal of the toxicity but not the antitumour activity of lometrexol by folic acid. Proc Amer Assoc Cancer Res 32:324, 1991
11. Alati T, Shih C, Pohland RC, Lantz RJ, Grindy GB: Evaluation of the mechanism(s) of inhibition of the toxicity, but not the antitumor activity of lometrexol (DDATHF) by folic aci. Proc Am Assoc Cancer Res 33: 407, 1992
12. Wedge SR, Laohavinij S, Taylor GA, Boddy A, Calvert AH, Newell DR: Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolic acid (lometrexol) administration with an oral folic acid supplement. Clin Cancer Res 1:1479-1486, 1995
13. Moran RG, Baldwin SW, Taylor EC, Shih C: The 6S- and 6R-diastereomers of 5,10-5,6,7,8-tetrahydrofolate are equiactive inhibitors de novo purine synthesis. J Biol Chem 264:21047-21051, 1989
14. Pizzorno G, Cashmore AR, Moroson BA, Beardsley GP: Leucovorin (LV): a "rescue" agent for 6(R)-5,10-dideazatetrahydrofolic acid (DDATHF). Proc AACR 31:339, 1990
15. Herbert V: Folic acid. Annu Rev Med 16:359-370, 1965
16. Rossi E, Ferraccioli GF, Cavalieri F, Menta R, Dall'Aglio PP, Migone L: Diclofenac-associated acute renal failure. Nephron 40:491-493, 1985
17. Clive DM, Stoff JS: Renal syndromes associated with nonsteroidal anti-inflammatory drugs. New Engl J Med 310:563-572, 1984
18. Zipser RD, Hoefs JC, Speckart PF, Zia PK, Horton R: Prostaglandins: modulators of renal function and presser resistance in chronic liver disease. J Clin Endocrinol Metab 48:895-900, 1979
19. Thyss A, Milano G, Kubar J, Namer M: Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet 256-258, 1986
20. Ellison NM, Servi RJ: Acute renal failure and death following sequential intermediate-dose methotrexate and 5-FU: a possible adverse effect due to concomitant indomethacin administration. Cancer Treat Rep 69:342-343, 1985
21. Fox RM: Methotrexate nephrotoxicity. Clin Exp Pharmacol Physiol 5:43-45, 1979
22. Jacobs SA, Stoller RG, Chabner BA, Johns DG: 7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. J Clin Invest 57:534-538, 1976
23. Pitman SW, Parker LM, Tattersall MHN et al.: Clinical trial of high dose methotrexate (NSC-740) with citrovorum factor (NSC-3590)-toxicology and therapeutic observations. Cancer Chemother Rep 6(1):43-49, 1975
24. Newell DR, Siddik ZH, Calvert AH, Jackman AL, Alison DL, McGhee KG, Harrap KR: Pharmacokinetics and toxicity studies with CB 3717. Proc Amer Assoc Cancer Res 23:181, 1982
25. Alison DL, Newell DR, Sessa C, Harland SJ, Hart LI, Harrap KR, Calvert AH: The clinical pharmacokinetics of the novel antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717). Cancer Chemother Pharmacol 14:265-271, 1985
26. Pitman SW, Miller D, Weichselbaum R, Frei E: Weekly high dose methotrexate with leucovorin rescue as initial adjuvant therapy in advanced squamous cell carcinoma of the head and neck: a pilot study. In: Salmon SE, Jones SE (eds) Adjuvant Therapy of Cancer. Elsevier/North-Holland Biomedical Press, Amsterdam, 1977, pp 467-473
27. Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA: Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. New Engl J Med 297:630-634, 1977
28. Boarman DM, Allegra CJ: Intracellular metabolism of 5-formyl tetrahydrofolate in human breast and colon cell lines. Cancer Res 52:36-44, 1992
29. Bunni BA, Sirotnak FM, Otter GM, Priest DG: Disposition of leucovorin and its metabolites in the plasma, intestinal epithelium and intraperitoneal L1210 cells of methotrexate-pretreated mice. Cancer Chemother Pharmacol 34:455-458, 1994
30. Saugstad OD: Hypoxanthine as a measurement of hypoxia. Pediat Res 9:158-161, 1975
31. Zakaria M, Brown PR, Fames MP, Barker BE: HPLC analysis of aromatic amino acids, nucleosides and bases in plasma of acute lymphocytic leukemics on chemotherapy. Clin Chim Acta 126:69-80, 1982
32. Wung WE, Howell SB: Hypoxanthine concentrations in normal subjects and patients with solid tumors and leukemia. Cancer Res 44:3144-3148, 1984
33. Alati T, Lantz RJ, Grindey GB: Whole-body autoradiographic disposition and plasma pharmacokinetics of 5,10-dideazatetrahydrofolic acid in mice fed folic acid-deficient or regular diets. J Pharm Sci 83:1396-1399, 1994
34. Schmitz JC, Grindey GB, Schultz RM, Priest DG: Impact of dietary folic acid on reduced folates in mouse plasma and tissues. Biochem Pharmacol 48:319-325, 1994
35. Farber S, Diamond LK, Mercer RD et al.: Temporary remissions in acute leukaemia in children produced by folic acid antagonist 4-amethopteroylglutamic acid (aminopterin). New Engl J Med 238:787-793, 1948